Table 4.
Summary of interventions used in the clinical trials as prevention against severe acute respiratory syndrome coronavirus‐2 infection
| Prevention | Vaccines |
|---|---|
| Pre and postexposure prophylaxis | Recombinant novel coronavirus vaccine |
| Antiviral medications | (Adenovirus type 5 vector) |
| Hydroxychloroquine | aAPC vaccine |
| Chloroquine | Minigene vaccine |
| Lopinavir/ritonavir | Recombinant chimeric COVID‐19 epitope DC |
| Interferon alpha | BCG V |
| Camostat Mesylate | bacTRL‐Spike |
| Peginterferon λ‐1a | Measles |
| Nitazoxanide | RNA vaccine candidate |
| Anti‐inflammatory | mRNA‐1273 vaccine |
| Anakinra | Nanoparticle vaccine |
| Colchicine | Recombinant novel coronavirus (adenovirus type 2 vector) |
| Corticosteroids | ChAdOx1 nCoV‐19 |
| Immunomodulators | INO‐4800 |
| Levamisole and isoprinosine | Nonpharmacological interventions |
| Lactobacillus coryniformis K8 | App‐based social distancing |
| Lenzilumab | Face masks vs N95 respirator |
| Miscellaneous | Internet‐based solutions |
| Vitamin C; vitamin D; zinc | Isolation strategy |
| Melatonin | |
| Mycobacterium w | |
| rhIFNa nasal drops | |
| Resistant potato starch | |
| Nitric oxide | |
| Bêta‐cyclodextrin and Citrox mouthwash | |
| Povidone‐iodine 0.5% nasal |